Treatment Trends for Muscle-Invasive Bladder Cancer in Germany from 2006 to 2019

In their recently published work in World Journal of Urology, Flegar et al. investigated treatment trends for muscle-invasive bladder cancer (MIBC) in Germany from 2006 to 2019. In this population-based study, the authors were able to show, that three out of four patients in Germany diagnosed with bladder cancer stage ≥T2 receive radical cystectomy as their primary treatment approach. Initially, the authors planned a comparison study of Germany and the USA but had to waive the comparison since the SEER database seems to underestimate the share of patients receiving radical cystectomy in the USA.

Further, the authors showed that multimodality treatment for MIBC increased and chemotherapy in combination with radical cystectomy was the most popular.

However, neoadjuvant chemotherapy is still underutilized in Germany. While case numbers for radical cystectomy increased, the authors described a slight tendency toward centralization of MIBC treatment.

Written by: Luka Flegar, K Kraywinkel, A Zacharis, C Aksoy, R Koch, N Eisenmenger, C Groeben, J Huber

Department of Urology, Philipps-University Marburg, Baldingerstr., Marburg, Germany., National Center for Cancer Registry Data, Robert Koch Institute, Berlin, Germany., Department of Urology, Philipps-University Marburg, Baldingerstr., Marburg, Germany., Department of Medical Statistics and Biometry, TU Dresden, Dresden, Germany., Reimbursement Institute RI Innovation GmbH, Hürth, Germany.

Read the Abstract

Login